ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1248

Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease

Ailia Ali1, Sarah Sun1, Faryal Shaikh1, Tamiko Katsumoto2, Neha Shah3, Kimberly Trotter1 and Pankti Reid4, 1University of Chicago, Chicago, IL, 2Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, 3Stanford University, Palo Alto, CA, 4University of Chicago Medical Center, Chicago, IL

Meeting: ACR Convergence 2025

Keywords: Access to care, autoimmune diseases, quality of life, socioeconomic factors, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Complementary and alternative medicine (CAM) use is increasingly prevalent among patients with rheumatic diseases, yet alignment between patient practices and clinician perspectives remains poorly defined. This study assesses CAM attitudes, usage patterns, and familiarity amongst both rheumatology clinicians and patients.

Methods: An online patient-facing survey and a separate clinician-facing survey evaluated use and perception of CAM in rheumatic diseases. Eligible patients were ≥ 18 years old and actively going to rheumatology clinic. Clinicians included rheumatology MDs, DOs and advanced practice providers. Dissemination of the survey was done virtually through patient advocacy groups, provider organizations, social media, and messaging via electronic medical records. Results were analyzed using descriptive statistics (Chi-square).

Results: 1221 patients with rheumatic disease across the United States completed the patient survey. For patients, if no familiarity with CAM (163 patients or 13% of respondents) was endorsed, the survey was ended. Patient participants were primarily female (88%), and predominantly Caucasian non-Hispanic (64%). The most common rheumatic disease reported was rheumatoid arthritis (58%) followed by Sjogren’s disease (19%). A high proportion of patients reported CAM usage but many were not familiar with CAM and 76% of patients did not find CAM very accessible. Most patients used the internet or social media as their primary source of information on CAM (40%). Half of the patients had Medicare insurance; of these patients, 26% reported daily CAM usage. There was no difference in CAM usage when comparing Medicare vs. non-Medicare patients (p >0.05). Asian respondents reported high daily usage of CAM while Black respondents had a lower daily usage compared to other groups (p=0.02). While patients with higher level education were more likely to use CAM (doctorate or higher with daily: 37.5% and monthly: 12.5% CAM use, master’s and college degrees: 35% daily and 7% monthly use), individuals with high school or less education were more likely to never use CAM (35%). A total of 128 rheumatologists across the United States completed the clinician survey. The majority of respondents were community rheumatologists (47%) and academic rheumatologists (40%). Most were female (66%) and the most common racial background was Asian (42%) and Caucasian-Non Hispanic (38%). Notably, 95.2% of respondents expressed support for integrating CAM therapies into standard rheumatology practice, indicating strong professional interest across practice settings.

Conclusion: CAM usage is prevalent amongst the rheumatic patient population but many patients do not find CAM very accessible and usage varies with different races/ethnicities and education levels. Future implementation needs to focus on more accessible CAM programs. As these patients follow regularly with their rheumatologists, the strong clinician interest for CAM integration into standard rheumatologic care is an opportunity to develop structured education and provide evidence-based resources for patients.

Supporting image 1Table 1: Patient Demographics

Supporting image 2Figure 1: Clinician Belief in Integrating CAM into Rheumatic Disease Care


Disclosures: A. Ali: None; S. Sun: None; F. Shaikh: None; T. Katsumoto: Beyond Meat, 12, Unrestricted grant, Sanofi, 5; N. Shah: Beyond Meat, 5, Impossible Foods, 11, Oura Ring, 11, Upside Foods, 11; K. Trotter: American College of Rheumatology, 1, Gsk, 1, Iridium, 6; P. Reid: AbbVie/Abbott, 1, Amgen, 6, Mustang Bio, 1, UCB, 1.

To cite this abstract in AMA style:

Ali A, Sun S, Shaikh F, Katsumoto T, Shah N, Trotter K, Reid P. Patient and Clinician Perception and Use of Complementary and Alternative (CAM) Medicine for Rheumatic Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/patient-and-clinician-perception-and-use-of-complementary-and-alternative-cam-medicine-for-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-clinician-perception-and-use-of-complementary-and-alternative-cam-medicine-for-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology